260 related articles for article (PubMed ID: 27140516)
21. DSA-FXM: Accelerated Donor-specific Flow Crossmatch Discriminating Class I and II Antibody Specifically and Only to Donor HLA for Determining True Incompatibility.
Chen G; Lin L; Tyan DB
Transplantation; 2020 Apr; 104(4):813-822. PubMed ID: 31385929
[TBL] [Abstract][Full Text] [Related]
22. Using HLA antibody detection, monitoring, and treatment to improve long-term allograft survival.
Everly MJ
Clin Transpl; 2010; ():317-22. PubMed ID: 21696049
[TBL] [Abstract][Full Text] [Related]
23. Summarizing the use of donor specific anti-HLA antibody monitoring in transplant patients.
Everly MJ
Clin Transpl; 2011; ():333-6. PubMed ID: 22755427
[TBL] [Abstract][Full Text] [Related]
24. Highly Sensitized Patients Are Well Served by Receiving a Compatible Organ Offer Based on Acceptable Mismatches.
Heidt S; Haasnoot GW; van der Linden-van Oevelen MJH; Claas FHJ
Front Immunol; 2021; 12():687254. PubMed ID: 34248971
[TBL] [Abstract][Full Text] [Related]
25. Unexpected Positive Prospective Crossmatches in Organ Transplant.
Desoutter J; Apithy MJ; Guillaume N
Exp Clin Transplant; 2017 Jun; 15(3):253-259. PubMed ID: 28447927
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.
Bailly E; Anglicheau D; Blancho G; Gatault P; Vuiblet V; Chatelet V; Morelon E; Malvezzi P; Parissiadis A; Tourret J; Guidicelli G; Sayegh J; Mousson C; Grimbert P; Top I; Le Quintrec M; Purgus R; Westeel PF; Proust B; Chabot V; Lebranchu Y; Dehaut F; Büchler M
Transplantation; 2018 Apr; 102(4):688-698. PubMed ID: 29135832
[TBL] [Abstract][Full Text] [Related]
27. Utility of the virtual crossmatch in solid organ transplantation.
Amico P; Hönger G; Steiger J; Schaub S
Curr Opin Organ Transplant; 2009 Dec; 14(6):656-61. PubMed ID: 19741534
[TBL] [Abstract][Full Text] [Related]
28. Transplanting Sensitized Kidney Transplant Patients With Equivalent Outcomes Utilizing Stringent HLA Crossmatching.
Rohan VS; Taber DJ; Moussa O; Pilch NA; Denmark S; Meadows HB; McGillicuddy JW; Chavin KD; Baliga PK; Bratton CF
Exp Clin Transplant; 2017 Feb; 15(1):47-55. PubMed ID: 27267614
[TBL] [Abstract][Full Text] [Related]
29. General insufficiency of the classical CDC-based crossmatch to detect donor-specific anti-HLA antibodies leading to invalid results under recipients' medical treatment or underlying diseases.
Schlaf G; Mauz-Körholz C; Ott U; Leike S; Altermann W
Histol Histopathol; 2012 Jan; 27(1):31-8. PubMed ID: 22127594
[TBL] [Abstract][Full Text] [Related]
30. IgG4 donor-specific HLA antibody profile is associated with subclinical rejection in stable pediatric liver recipients.
Jackson AM; Kanaparthi S; Burrell BE; Lucas DP; Vega RM; Demetris AJ; Feng S
Am J Transplant; 2020 Feb; 20(2):513-524. PubMed ID: 31561279
[TBL] [Abstract][Full Text] [Related]
31. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
[TBL] [Abstract][Full Text] [Related]
32. Current approaches for risk assessment of intestinal transplant patients: A view from the histocompatibility laboratory.
Xu Q; Zeevi A; Ganoza A; Cruz RJ; Mazariegos GV
Hum Immunol; 2024 May; 85(3):110768. PubMed ID: 38433035
[TBL] [Abstract][Full Text] [Related]
33. Comparison Between Total IgG, C1q, and C3d Single Antigen Bead Assays in Detecting Class I Complement-Binding Anti-HLA Antibodies.
Moreno Gonzales MA; Mitema DG; Smith BH; Schinstock CA; Stegall MD; Wakefield LL; Henderson NA; DeGoey SR; Kreuter JD; Gandhi MJ
Transplant Proc; 2017 Nov; 49(9):2031-2035. PubMed ID: 29149956
[TBL] [Abstract][Full Text] [Related]
34. Monitoring of Donor-specific Anti-HLA Antibodies and Management of Immunosuppression in Kidney Transplant Recipients: An Evidence-based Expert Paper.
Crespo M; Zárraga S; Alonso Á; Beneyto I; Díaz Corte C; Fernandez Rodriguez AM; Franco A; Hernández D; González-Roncero FM; Jiménez Martín C; Jimeno L; Lauzurica Valdemoros LR; Llorente S; Mazuecos A; Osuna A; Ramos JP; Rodríguez Benot A; Ruiz San Millán JC; Sánchez Fructuoso A; Torregrosa JV; Guirado L;
Transplantation; 2020 Aug; 104(8 Suppl 2):S1-S12. PubMed ID: 32658025
[No Abstract] [Full Text] [Related]
35. [Pitfalls in interpreting anti-HLA antibodies by Luminex technology].
Moalic-Allain V
Ann Biol Clin (Paris); 2014; 72(2):178-84. PubMed ID: 24736137
[TBL] [Abstract][Full Text] [Related]
36. The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients.
OʼLeary JG; Samaniego M; Barrio MC; Potena L; Zeevi A; Djamali A; Cozzi E
Transplantation; 2016 Jan; 100(1):39-53. PubMed ID: 26680372
[TBL] [Abstract][Full Text] [Related]
37. Quantifying HLA-specific antibodies in patients undergoing desensitization.
Zachary A; Reinsmoen NL
Curr Opin Organ Transplant; 2011 Aug; 16(4):410-5. PubMed ID: 21666475
[TBL] [Abstract][Full Text] [Related]
38. Impact of donor-specific HLA antibodies in transplantation, a review of the literature published in the last three years.
Kaneku H
Clin Transpl; 2010; ():283-306. PubMed ID: 21696047
[TBL] [Abstract][Full Text] [Related]
39. Clinical management of renal transplant patients with donor-specific alloantibody: the state of the art.
Stegall MD
Clin Transpl; 2010; ():307-15. PubMed ID: 21696048
[TBL] [Abstract][Full Text] [Related]
40. Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantation.
Cuadrado A; San Segundo D; López-Hoyos M; Crespo J; Fábrega E
World J Gastroenterol; 2015 Oct; 21(39):11016-26. PubMed ID: 26494958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
